Ponezumab

Ponezumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	beta-amyloid
Clinical data
ATC code	none
Identifiers
CAS Number	1178862-65-1^N
ChemSpider	none
UNII	1TG15H1XE9^Y
Chemical and physical data
Formula	C₆₅₅₂H₁₀₁₅₈N₁₇₃₀O₂₀₉₀S₅₂
Molar mass	148.3 kg/mol
^NY (what is this?) (verify)

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.^[1]

Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.^[2] Detailed reports have to be released.

References

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone ("-os-", "-s(o)-")

Human ("-osu-")	Burosumab Denosumab

Humanized ("-sozu-")	Blosozumab Romosozumab

Musculoskeletal ("-mul-")

Human ("-mulu-")	Stamulumab^†

Circulatory ("-c(i[r])-")

Human ("-ciru-")	Alirocumab Ascrinvacumab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab Vesencumab

Mouse ("-ciro-")	Biciromab^‡ Imciromab^‡

Chimeric ("-cixi-")	Abciximab Volociximab

Humanized ("-cizu-")	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Etaracizumab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic ("-ne(u)(r)-")

Human ("-neru-")	Aducanumab Atinumab Erenumab Fasinumab Fulranumab Gantenerumab Opicinumab

Humanized ("-nezu-"/"-neuzu-")	Bapineuzumab^† Crenezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Solanezumab Tanezumab

Angiogenesis inhibitor ("-anibi-")

Humanized ("-anibizu-")	Ranibizumab

Growth factor ("-gr(o)-")

Human ("-gru-")	Bimagrumab

Humanized ("-grozu-")	Domagrozumab Landogrozumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the 10/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.